Clinical Trials Directory

Trials / Completed

CompletedNCT02196129

Immediate Pain Relieving Effects of Sinbaro-3 for Low Back Pain

Immediate Pain Relieving Effects of Sinbaro-3 Pharmaco-acupuncture in Low Back Pain Patients; A Randomized Controlled Trial

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Jaseng Hospital of Korean Medicine · Academic / Other
Sex
All
Age
18 Years – 69 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate the immediate pain relieving effects of sinbaro-3 pharmaco-acupuncture in patients with low back pain admitted for inpatient care

Detailed description

60 patients with LBP with moderate to severe pain(NRS\>6) were randomly allocated to 2 groups. The experimental group was treated with sinbaro-3 pharmacoacupuncture and the control group was treated with Hwangryun pharmacoacupuncture. All administrations were limited to 1 session, and comparisons of measurements were made before and after treatment. Primary outcomes were measured using the VAS scale. Post-treatment follow-up will be performed to measure primary outcomes at 30 minutes, 2hours, 4hours, and 6 hours after treatment. Before and after each measurement, the patients are asked to stand up and rotate their torso. At termination of the study, satisfaction levels of the patient's current status will also be collected.

Conditions

Interventions

TypeNameDescription
DRUGSinbaro-31cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
DRUGHwangryun1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain

Timeline

Start date
2014-07-01
Primary completion
2014-10-01
Completion
2014-11-01
First posted
2014-07-21
Last updated
2018-11-07

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT02196129. Inclusion in this directory is not an endorsement.